Form 990 for tax year 2023

Totals

Total revenue

$1,699,784

Total expenses

$1,411,492

Contributions and grants received

$1,691,690

Grants paid

$245,000

Program service revenue

$0

Investment income

$8,094

Other revenue

$0

Total assets, end of year

$2,482,026

Total liabilities, end of year

$0

Net assets or fund balances, end of year

$2,482,026

Program services expenses (Part IX)

$1,216,828

Management and general expenses

$138,248

Fundraising expenses

$56,416

Program service expenses (Part III)

$1,216,828

Program services were 86.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• THE RESEARCH ACHIEVEMENTS OF THE GLIOBLASTOMA FOUNDATION IN 2023 INVOLVED CONTINUING FUNDING FOR LEADING EDGE RESEARCH FOR TARGETED TREATMENTS FOR GLIOBLASTOMA, PROVIDING PATIENT SUPPORT RESOURCES FOR FAMILIES AND PATIENTS DIAGNOSED WITH GLIOBLASTOMA, AND RAISING AWARENESS OF THIS RARE GRADE 4 BRAIN CANCER. DURING THE 2023 YEAR WE CONTINUED TO FUND RESEARCH FOR THE COMBINATION DRUG THERAPY OF LOMUSTINE AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS, FUNDED RESEARCH INTO PATIENT AND CAREGIVER QUALIFY OF LIFE AFTER DIAGNOSIS RESEARCH, AND A TARGETED RESEARCH STUDY ON GLIOBLASTOMA CANCER CELL METABOLISM PROCESSES AND DRUGS TO STOP GLIOBLASTOMA CELL GROWTH. WE ALSO MOVED FORWARD ON OUR GOAL TO MANUFACTURE LOMUSTINE AT A REDUCED RATE FOR PATIENTS BY PARTNERING WITH CONTINUITY PHARMA IN THE PRODUCTIVE OF LOMUSTINE ACTIVE PHARMACEUTICAL INGREDIENT. THIS PROJECT IS CURRENTLY UNDERWAY TO BRING LOMUSTINE TO PATIENTS AT A LOWER COST. WE ALSO CONTINUED OUR PATIENT PROGRAMS TO PROVIDE CLINICAL TRIALS MATCHING TO PATIENTS AFTER A GLIOBLASTOMA DIAGNOSIS AND CONTINUED TO HOST OUR AWARD-WINNING SUPPORT GROUP FOR PATIENTS AND CAREGIVERS, CALLED THE GLIOBLASTOMA SUPPORT CIRCLE.

  Expenses $1,216,828 · Grants $245,000

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  $100,000

  GLIOBLASTOMA RESEARCH

• DUKE UNIVERSITY HOSPITAL

  $75,000

  GLIOBLASTOMA RESEARCH

• MASS GENERAL HOSPITAL

  $30,000

  GLIOBLASTOMA RESEARCH

• YALE UNIVERSITY

  $30,000

  GLIOBLASTOMA RESEARCH

Provenance

Return type

form_990

Tax year

2023

Filed

11 June 2025

IRS schema version

2023v6.0

Source object

202531679349300823

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.